Burki T. European Commission classifies obesity as a chronic disease. Lancet Diabetes Endocrinol 2021;9:418.

Nam GE, Kim YH, Han K, Jung JH, Rhee EJ, Lee WY. Obesity fact sheet in Korea, 2020: prevalence of obesity by obesity class from 2009 to 2018. J Obes Metab Syndr 2021;30:141-8. https://doi.org/10.7570/jomes21056

Kim BY, Kang SM, Kang JH, et al. 2020 Korean Society for the Study of Obesity guidelines for the management of obesity in Korea. J Obes Metab Syndr 2021;30:81-92. https://doi.org/10.7570/jomes21022

Kim BY, Kang SM, Kang JH, et al. Current long-term pharmacotherapies for the management of obesity. J Obes Metab Syndr 2020;29:99-109. https://doi.org/10.7570/jomes20010

Fruh SM. Obesity: risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract 2017;29:S3-14.

Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep 2019;19:96. https://doi.org/10.1007/s11892-019-1220-8

Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22. https://doi.org/10.1056/NEJMoa1411892

O'Neil PM, Aroda VR, Astrup A, et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab 2017;19:1529-36. https://doi.org/10.1111/dom.12963

Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2017;74:719-28. https://doi.org/10.1001/jamapsychiatry.2017.1220

Camkurt MA, Lavagnino L, Zhang XY, Teixeira AL. Liraglutide for psychiatric disorders: clinical evidence and challenges. Horm Mol Biol Clin Investig 2018;36:20180031. https://doi.org/10.1515/hmbci-2018-0031

Weina H, Yuhu N, Christian H, Birong L, Feiyu S, Le W. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity. Brain Res 2018;1694:55-62. https://doi.org/10.1016/j.brainres.2018.04.031

U.S. Food and Drug Administration. SAXENDA (liraglutide [rDNA origin] injection), solution for subcutaneous use [Internet]. U.S. Food and Drug Administration. 2014 [cited 2022 May 3]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf